{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-21-142578","form_type":"8-K","ticker":"TWST","cik":"0001581280","company_name":"Twist Bioscience Corp","filed_at":"2021-11-22T23:59:59+00:00","discovered_at":"2026-05-14T18:04:13.140340+00:00","generated_at":"2026-06-28T06:07:46.764308+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Twist Bioscience reports record FY2021 revenue $132.3M (+47% YoY), guides FY2022 rev $183M-$193M","bullets":["FY2021 revenue $132.3M, up 47% from $90.1M; net loss $152.1M vs $139.9M.","Q4 revenue $38.0M (+17% YoY); net loss $41.2M ($0.84/share) vs $24.3M ($0.54/share).","FY2022 revenue guidance $183M-$193M, representing ~42% growth at midpoint.","Cash and investments $477.9M at Sept 30, 2021.","Announced acquisition of Abveris to add in vivo antibody discovery capabilities."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-21-142578","json":"https://secwatch.observer/filing/0001104659-21-142578.json","markdown":"https://secwatch.observer/filing/0001104659-21-142578.md","text":"https://secwatch.observer/filing/0001104659-21-142578.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1581280/000110465921142578/0001104659-21-142578-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1581280/000110465921142578/tm2133571d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T06:07:46.764308+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}